RxDoctor Payments Data

Lavone Smith, MD

Advanced Heart Failure and Transplant Cardiology · Richmond, VANPI 1710256094

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,250 of the $22,603 with a category attached, or 63.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 69.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $12,768 and has fallen 93.4% since, to $837 in 2025.

$22,603in general payments, 2019–2025

Across 306 payments — averaging $73.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16K
  • Abbott$3K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Pfizer$568
  • Novartis$328
  • Cvrx, Inc.$308
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$14,25063%
  • Travel & lodging$3131%
  • Food & beverage$7,75634%
  • Education$2841%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,603 in reported general payments places this provider in the 75th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.

See all advanced heart failure and transplant cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$68,234
Medicare patients
127
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis32$731,737
EntrestoSacubitril/Valsartan126$117,667
JardianceEmpagliflozin121$114,238
FarxigaDapagliflozin Propanediol50$49,398
Bumetanide86$2,271
Hydralazine Hcl59$842
Spironolactone166$752
Potassium Chloride34$658
Carvedilol83$632
Rosuvastatin Calcium19$618
Metoprolol Succinate49$452
Allopurinol52$424
Atorvastatin Calcium60$371
Sildenafil Citrate12$329
Torsemide21$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax$568$731,73732 claims
NovartisEntresto$328$117,667126 claims
Boehringer IngelheimJardiance$192$114,238121 claims
AstraZenecaFarxiga$162$49,39850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.

Other advanced heart failure and transplant cardiology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →